


Our Docket No.: VPI/02-119 US



Certificate Of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On February 9, 2004.
Date

1. Information Disclosure Statement (in duplicate);
2. PTO-1449 Form (in duplicate);
3. Copy of International Search Report;
4. Cited References (B1-B4); and
5. This Return Postcard Receipt.


Signature

Karen DiRocco
Typed or printed name of person signing Certificate



Docket No.: VPI/02-119 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Forster, et al.
SERIAL NUMBER: 10/632,340 EXAMINER: Not Yet Assigned
FILING DATE: August 1, 2003 ART UNIT: 1614
FOR: COMPOSITIONS USEFUL AS INHIBITORS OF GSK-3

February 9, 2004
Cambridge, Massachusetts

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being been filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. (37 C.F.R. §1.97).


A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

APPLICANTS: Forster, et al.
U.S.S.N.: 10/632,340


By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/02-119 US.

Respectfully submitted,



Andrea L.C. Robidoux, Reg. No. 47,902
Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
130 Waverly Street
Cambridge, Massachusetts 02139
Tel: (617) 444-6731
Fax: (617) 444-6483



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/632,340
	Filing Date	August 1, 2003
	First Named Inventor	Cornelia J. Forster
	Group Art Unit	1614
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	VPI/02-119 US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1	WO 03/049739	Vertex Pharmaceuticals Incorporated	19 June 2003		
	B2	WO 02/50065	Vertex Pharmaceuticals Incorporated	27 June 2002		
	B3	WO 02/22601	Vertex Pharmaceuticals Incorporated	21 March 2002		
	B4	WO 01/79198	Agouron Pharmaceuticals Inc.	25 October 2001		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.